The announcement of a $35 per month out-of-pocket cap for insulin for some individuals with Medicare is a real victory for the American Diabetes Association and for people with diabetes, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.
The announcement of a $35 per month out-of-pocket cap for insulin for some individuals with Medicare is a real victory for the American Diabetes Association and for people with diabetes, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.
Transcript:
How will Medicare's $35 per month out-of-pocket cap for insulin affect pricing policy for other people who rely on insulin?
For individuals that have the appropriate Medicare plans, it will significantly reduce the cost of insulin, and we're very excited about that. That's a real victory for the ADA and most importantly for people with diabetes. What we hope is that commercial payers and others will follow suit and be able to adopt similar programs. Some have. Again, this has been a wonderful, private-public partnership fostered by ADA's advocacy to reach this point. We hope to be able to extend this to all people that require insulin.
You are well known for implementing the patient-centered medical home and the medical neighborhood. How will you bring this experience to others in your new role at ADA?
Within the science and medicine portion of the ADA, where we really engage the wide breadth of professionals focused on diabetes, the plan will be, and the hope, of course, most people with diabetes are cared for by primary care providers. To be able to reach out to that constituency group, and engage them in ways to be able to improve care, will really have an opportunity to have a dramatic impact. One of the ways that ADA has been doing that, and we'll be launching a larger program that you'll hear about in the coming weeks, is around reducing therapeutic inertia that will leverage the patient-centered medical home and the neighborhood to improve the outcomes once again for people with diabetes.
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
What We’re Reading: UnitedHealth Lawsuit; Fentanyl Crackdown; Global Heat Deaths Increase
November 15th 2023A class action lawsuit was filed against UnitedHealth Group and a subsidiary for allegedly using an algorithm to deny rehabilitation coverage for seriously ill patients; US and China officials are finalizing an agreement to crack down on fentanyl; a study published Tuesday projected global heat deaths to increase by 370% if no action is taken against global warming.
Read More